Peptide-Based PET Imaging Agent [ 68 Ga]Ga-DOTA-NT-20.3-Ibu for Noninvasive Evaluation of Tumor Neurotensin Receptor 1 Expression
Molecular Pharmaceutics · 02.03.2026 · 23 (3) · 2131-2141
DOI: 10.1021/acs.molpharmaceut.5c01915 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 26.01.2026. Verfasst von Xiufeng Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Universi…. Hauptthemen laut MEDLINE: Receptors, Neurotensin, Positron-Emission Tomography, Gallium Radioisotopes, Radiopharmaceuticals. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Guangdong Provincial People's Hospital.
Abstract (Originalsprache)
High neurotensin receptor 1 (NTSR1) expression is strongly associated with progression and poor prognosis across multiple malignancies. We designed an NTSR1-targeted peptide-based PET probe conjugated with the albumin-binding moiety ibuprofen, designated [68Ga]Ga-DOTA-NT-20.3-Ibu, which was synthesized with high radiochemical yield and purity, exhibited sufficient in vitro stability, and demonstrated favorable serum albumin-binding capacity. Cell binding/uptake assays, animal-based PET imaging, and biodistribution studies confirmed the radiotracer's high affinity and specificity for NTSR1. In human participants, [68Ga]Ga-DOTA-NT-20.3-Ibu was safe and primarily excreted via the urinary system. Bone marrow uptake was detectable with SUVmean of 4.11 ± 1.59 and 4.99 ± 1.82 at 60 and 120 min postinjection, respectively. Mild uptake was observed in the blood pool, liver, spleen, pancreas, stomach, and bowel, while other tissues showed minimal uptake. Importantly, lung tumor uptake of [68Ga]Ga-DOTA-NT-20.3-Ibu correlated with NTSR1 expression levels. Collectively, [68Ga]Ga-DOTA-NT-20.3-Ibu PET enables accurate, noninvasive assessment of tumor NTSR1 expression, facilitating NTSR1-targeted cancer treatment and prognosis monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
- State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
ORCID-Profile: Zhen Cheng, Lei Jiang
Förderung
- National Key Research and Development Program of China
- Guangdong Provincial People's Hospital
Zitieren
APA
Liu, X., Chen, Y., Zhu, J., Zhang, W., Qian, K., Guo, D., Guo, Q., Wang, P., Cheng, Z., Yuan, H., & Jiang, L. (2026). Peptide-Based PET Imaging Agent [ 68 Ga]Ga-DOTA-NT-20.3-Ibu for Noninvasive Evaluation of Tumor Neurotensin Receptor 1 Expression. Molecular Pharmaceutics, 23(3), 2131-2141. https://doi.org/10.1021/acs.molpharmaceut.5c01915
Vancouver
Liu X, Chen Y, Zhu J, Zhang W, Qian K, Guo D, et al. Peptide-Based PET Imaging Agent [ 68 Ga]Ga-DOTA-NT-20.3-Ibu for Noninvasive Evaluation of Tumor Neurotensin Receptor 1 Expression. Molecular Pharmaceutics. 2026;23(3):2131-2141. doi:10.1021/acs.molpharmaceut.5c01915
BibTeX
@article{Liu2026,
author = {Liu, Xiufeng and Chen, Yang and Zhu, Jiamin and Zhang, Wenqing and Qian, Kun and Guo, Danyi and Guo, Qi and Wang, Peng and Cheng, Zhen and Yuan, Hui and Jiang, Lei},
title = {Peptide-Based PET Imaging Agent [ 68 Ga]Ga-DOTA-NT-20.3-Ibu for Noninvasive Evaluation of Tumor Neurotensin Receptor 1 Expression},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {3},
pages = {2131--2141},
doi = {10.1021/acs.molpharmaceut.5c01915}
}
EUVIMED